Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs (REGENDER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02866565|
Recruitment Status : Not yet recruiting
First Posted : August 15, 2016
Last Update Posted : August 15, 2016
Diabetic foot ulcer (DFU) is a major complication and the leading cause of hospitalization among people with diabetes mellitus. It occurs in 15% of all patients with diabetes and precedes 84% of all lower leg amputations. Despite many therapeutic advances over the past decades, including dressings (hydrocolloids, alginate, skin substitutes) and growth factors, healing rates of DFU remain low.
Mechanisms of faulty wound healing in diabetic patients are complex, related to both intrinsic and extrinsic factors. The main reasons for impaired healing appears to be: 1/exhaustion of local cell populations that promote wound healing; 2/excessive production of matrix metalloproteases (MMPs) coupled with reduced expression of the tissue inhibitors of MMPs; 3/impaired neovascularisation coupled with reduced numbers of endothelial progenitor cells and impairment of their functioning. These imbalances may result in excessive degradation of extracellular matrix components, as well as an inappropriate local inflammatory response .
Adipose-derived stroma vascular fraction provides a rich and easily accessible source of autologous cells for regenerative medicine applications. Il contains multipotent stem cells and progenitors called adipose-derived regenerative cells (ADRCs) able to stimulate wound healing. There are attracted to the wound site where they supplement the wound bed with similar cell types, secrete numerous growth factors and cytokines, increase macrophage recruitment, enhance granulation tissue, and improve vascularisation . The reparative capabilities coupled with good safety of ADRCs have been illustrated in a study for treating severe and irreversible radiation-induced lesions, and in a study for treating sclerodactyly in patients with diffuse scleroderma. Numerous case reports showing healing of refractory wounds following treatment with autologous ADRCs have also been reported.
Based on these previous reports, the present study aims to assess the efficacy and tolerance of injection of ADRCs for the local treatment of neuropathic or neuro-ischemic DFU.
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Foot Ulcer||Drug: adipose-derived regenerative cells (ADRCs)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||45 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||February 2017|
|Estimated Primary Completion Date :||February 2019|
|Estimated Study Completion Date :||November 2019|
|Experimental: Diabetic foot ulcer||
Drug: adipose-derived regenerative cells (ADRCs)
- Percentage of patients achieving 100% wound closure [ Time Frame: 20 WEEKS ]
- time to reach complete wound closure [ Time Frame: 20 WEEKS ]
- wound surface regression in relative value [ Time Frame: 20 weeks ]
- wound surface regression in absolute value [ Time Frame: 20 weeks ]
- percentage of patients achieving 50 % wound closure [ Time Frame: 20 weeks ]
- ulcer recurrence rate [ Time Frame: 20 weeks ]
- change in quality of life assessed by the SF-36 QoL survey from baseline [ Time Frame: 20weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02866565
|Contact: PATRICE DARMONemail@example.com|
|Contact: alexandra GIULIANIfirstname.lastname@example.org|
|Assistance Publique Hopitaux de Marseille||Not yet recruiting|
|Contact: PATRICE DARMON email@example.com|
|Principal Investigator: PATRICE DARMON|
|Study Director:||catherine GEINDRE||Assistance Publique Hopitaux De Marseille|
|Principal Investigator:||PATRICE DARMON||Assistance Publique Hopitaux De Marseille|